Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Incoloy Alloy Spring Wire
Contact UsWe adhere to the business philosophy of “gathering all the steel in the world and achieving stainless quality”, sincerely looking forward to the joining and cooperation of domestic and foreign merchants, new and old users, and working together to create brilliance
-
7000A 12V&24V Jump Starter for Truck Starting in -40C
Contact Us（*For Jump Starter ODM/OEM Solutions, secure your exclusive quotation now!）
-
PGA temporary plugging agent
Contact UsPGA fully degradable temporary plugging agent is temporary plugging agent developed mainly with degradable materials to meet the needs of oil fields under various temperatures and working conditions.
-
Spine Solutions
Contact UsUsed in kyphoplasty, the vertebra is enlarged to create a cavity so that bone cement can be injected to restore and stabilize the vertebra.
Reviews
There are no reviews yet.